, the Federal Trade Commission (FTC) issued a complaint alleging that unsubstantiated superiority claims were made in advertisements for Doan's analgesic products. In addition, the FTC sought an order against the Novartis Corporation that required corrective advertising in all Doan's advertisements and packaging. As a result, FTC v. Novartis was unique because it was the FTC's first litigated corrective advertising case since Warner-Lambert, nearly 25 years ago. The case presented an opportunity for the Commission to indicate the types of consumer research needed in six areas: deception assessment, materiality analysis, belief measurement, ad-belief linkage, lingering effects estimation, and remedy calibration. In each of these areas, the FTC presented substantial evidence to support a strong corrective advertising remedy. However, although the Commission ordered corrective advertising, its weak remedy will inevitably fall far short of correcting consumer misbeliefs about Doan's.